Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages

Key Points

• Analysts: Achieve Life Sciences has an average recommendation of "Buy" from six covering firms (1 sell, 3 buy, 2 strong buy) with an average 1‑year target of $14.67.
• Stock and financials: ACHV opened at $4.15, trades in a 12‑month range of $2.00–$6.03, has a market cap of $220.9M and a negative P/E of -3.19, and analysts expect -1.34 EPS for the current year.
• Business and recent results: The clinical‑stage biotech is developing cytisinicline for smoking cessation and reported Q1 EPS of ($0.28), missing consensus by $0.01.

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $14.6667.

Several research firms have issued reports on ACHV. Weiss Ratings reiterated a "sell (d-)" rating on shares of Achieve Life Sciences in a research report on Friday, March 27th. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Finally, Canaccord Genuity Group set a $13.00 target price on Achieve Life Sciences and gave the stock a "buy" rating in a research report on Monday.

Achieve Life Sciences Stock Performance

NASDAQ ACHV opened at $4.15 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.52. The business's 50 day moving average is $3.93 and its two-hundred day moving average is $4.37. Achieve Life Sciences has a 12-month low of $2.00 and a 12-month high of $6.03. The stock has a market capitalization of $220.90 million, a price-to-earnings ratio of -3.19 and a beta of 1.96.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). Research analysts expect that Achieve Life Sciences will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Several institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC boosted its stake in shares of Achieve Life Sciences by 10.7% during the 3rd quarter. ADAR1 Capital Management LLC now owns 47,800 shares of the biopharmaceutical company's stock worth $151,000 after acquiring an additional 4,627 shares in the last quarter. Manchester Financial Inc. boosted its stake in shares of Achieve Life Sciences by 12.1% during the 1st quarter. Manchester Financial Inc. now owns 66,222 shares of the biopharmaceutical company's stock worth $195,000 after acquiring an additional 7,138 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Achieve Life Sciences by 39.9% during the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 9,617 shares in the last quarter. Robertson Stephens Wealth Management LLC boosted its stake in shares of Achieve Life Sciences by 100.0% during the 4th quarter. Robertson Stephens Wealth Management LLC now owns 20,000 shares of the biopharmaceutical company's stock worth $99,000 after acquiring an additional 10,000 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Achieve Life Sciences during the 1st quarter worth approximately $32,000. Hedge funds and other institutional investors own 33.52% of the company's stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc NASDAQ: ACHV is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.